It is tempting to speculate that the antiapoptotic effects of IGF-1 hinder cancer therapies that target other PTKs, and that the antineoplastic effects observed when blocking a PTK may be significantly underestimated if examined only under conditions where IGF-IR is fully functional. Here, PTK2B is linked to cancer.